Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Web-Based Amblyopia Decision Support Tool.

JAMA ophthalmology·2026
Same author

Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern®.

Ophthalmology·2026
Same author

Myopia Control-Are We Getting Any Closer?

JAMA ophthalmology·2025
Same author

Validating Rules for Defining No Improvement of Visual Acuity in Childhood Amblyopia.

Investigative ophthalmology & visual science·2025
Same author

Quantitative comparison of vascular characteristics of plus disease images published over time: International Classification of Retinopathy of Prematurity.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2025
Same author

Doses of medial rectus muscle recessions for divergence insufficiency-type esotropia.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2024

Related Experiment Video

Updated: Jun 21, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Plus disease.

Bradley V Davitt1, David K Wallace

  • 1Departments of Ophthalmology and Pediatrics, Cardinal Glennon Children's Medical Center, Saint Louis University School of Medicine, 1465 South Grand Boulevard, St. Louis, Missouri 63104, USA. davittb@slu.edu

Survey of Ophthalmology
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Plus disease in retinopathy of prematurity (ROP) is a key indicator for severe cases. New objective methods are being developed to improve the subjective diagnosis of plus disease, aiding timely treatment.

More Related Videos

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Related Experiment Videos

Last Updated: Jun 21, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Area of Science:

  • Ophthalmology
  • Neonatology
  • Medical Imaging

Background:

  • Plus disease is a critical sign of severe retinopathy of prematurity (ROP).
  • The Early Treatment for ROP (ETROP) trial established plus disease as the primary indication for laser treatment.
  • Pre-plus disease, characterized by vascular changes, has been defined but diagnosis remains subjective.

Purpose of the Study:

  • To review the evolving understanding and diagnostic challenges of plus disease in ROP.
  • To highlight the development of objective methods for recognizing and quantifying retinal vascular abnormalities in ROP.
  • To explore the potential of semiautomated quantification to improve clinical judgment.

Main Methods:

  • Review of historical ROP trials and diagnostic criteria.
  • Discussion of the pathological basis of plus disease.
  • Overview of emerging semiautomated quantification techniques for retinal vascular morphology.

Main Results:

  • Plus disease is a primary indicator for ROP treatment, established by the ETROP trial.
  • Subjectivity in recognizing plus disease remains a significant diagnostic challenge.
  • Semiautomated methods show promise in objectively quantifying vascular changes.

Conclusions:

  • Objective quantification of retinal vascular abnormalities is crucial for improving ROP diagnosis.
  • Semiautomated methods can augment clinical judgment for timely ROP treatment.
  • Continued research into objective measures will enhance the management of severe ROP.